Smoothened inhibitor erismodegib combined with nilotinib in patients with chronic myeloid leukemia resistant/intolerant to at least one prior tyrosine kinase inhibitor: a phase 1b study.
Oliver Gerhard OttmannFrank StegelmannMassimo BrecciaJuan Luis SteegmannEduardo OlavarriaPaola AimoneJeffrey H LiptonPublished in: Leukemia & lymphoma (2020)
Keyphrases